Aan dit artikel is enkele uren gewerkt. Vertalen, interpreteren, relevante informatie erbij zoeken enz. Als u ons werk en kanker-actueel.nl waardeert dan wilt u ons misschein ondersteunen met een donatie, of direct al of niet anoniem op  RABO t.n.v. Stichting Gezondheid Actueel in Amersfoort.
Onze IBANcode is NL79 RABO 0372 9311 38

13 september 2017: Bron: J Glob Oncol. 2017 Aug; 3(4): 289–303. Published online 2017 Apr 11

Palbociclib samen met fulvestrand geeft verdubbeling van progressievrije ziekte en langere overall overleving in vergelijking met alleen fulvestrand bij hormoonresistente borstkanker.  Ook bij Aziatische vrouwen blijken die resultaten overeen te komen met niet-Azoatische vrouwen, zowel voor als na de overgang . Dit bljikt uit een vooraf geplande placebo gecontroleerde gerandomiseerde subgroep  binnen de PALOMA-3 studie. De resultaten uit de PALOMA-3 studie bij vrouwen met hormoonresistente borstkanker gaf een verdubbeling van progressievrije tijd te zien (4,6 vs 9,5 maanden) (zie abstract onderaan artikel. En is vergelijkbaar met een studie analyse bij een groep Aziatische vrouwen.

Deze groep van vrouwen waren allemaal van Aziatische afkomst, zowel premenopauzale en postmenopauzale. Zij hadden allemaal palbociclib plus fulvestrant (n = 71) of placebo plus fulvestrant (n = 31) gekregen als behandeling. Palbociclib plus fulvestrant verbeterde de progressie-vrije overleving (PFS) in vergelijking met fulvestrant alleen. Mediane PFS werd tot nu toe niet bereikt met palbociclib plus fulvestrant (95% CI, 9,2 maanden niet bereikt), maar was 5,8 maanden met placebo plus fulvestrant (95% CI, 3,5 tot 9,2 maanden, relatieve risicoi, 0,485, 95% CI, 0,270 tot 0,869 ; P = .0065).

Zie grafiek om vergeljiking te maken met niet-Aziatische vrouwen

Tekst gaat verder onder grafiek:

Palbociclib studie

De meest voorkomende graad 3 of 4 bijwerkingen in de palbociclibgroep waren neutropenie (92%) en leukopenie (29%); Febriele neutropenie bij 4,1% van de patiënten. Deze waren vergelijkbaar met de bijwerkingen bij niet-Aziatische vrouwen die palcociclib kregen.

Zie bijwerkingengrafiek:

An external file that holds a picture, illustration, etc.
Object name is JGO.2016.008318app1.jpg


Dit is het eerste studierapport, naar ons weten, dat Palbociclib plus fulvestrant PFS bij Aziatische patiënten verbetert. Palbociclib plus fulvestrant werd goed verdragen in deze studie.

Het volledige studierapport: PALOMA-3: Phase III Trial of Fulvestrant With or Without Palbociclib in Premenopausal and Postmenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That Progressed on Prior Endocrine Therapy—Safety and Efficacy in Asian Patients is gratis in te zien.

Hier het abstract van de studies:

Palbociclib plus fulvestrant treatment was well-tolerated, and the primary toxicity of asymptomatic neutropenia was effectively managed by dose modification without apparent loss of efficacy.

Source: The oncologist

doi: 10.1634/theoncologist.2016-0097

The Oncologist vol. 21 no. 10 1165-1175

Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3)

Sunil Vermaa, Cynthia Huang Bartlettb, Patrick Schnellc, Angela M. DeMicheled, Sherene Loie, Jungsil Rof, Marco Colleonig, Hiroji Iwatah, Nadia Harbecki, Massimo Cristofanillij, Ke Zhangk, Alexandra Thielel, Nicholas C. Turnerm and Hope S. Rugon + Author Affiliations aUniversity of Calgary, Alberta, Canada bPfizer Inc., Collegeville, Pennsylvania, USA cPfizer Inc., New York, New York, USA dUniversity of Pennsylvania, Philadelphia, Pennsylvania, USA ePeter MacCallum Cancer Centre, East Melbourne, Victoria, Australia fNational Cancer Center, Goyang-si, Republic of Korea gIstituto Europeo di Oncologia, Milan, Italy hAichi Cancer Center Hospital, Nagoya, Japan iBrustzentrum der Universität München, Munich, Germany jRobert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Chicago, Illinois, USA kPfizer Inc., San Diego, California, USA lPfizer Inc., Cambridge, Massachusetts, USA mInstitute of Cancer Research and Royal Marsden Hospital, London, United Kingdom nUniversity of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California, USA. Correspondence: Sunil Verma, M.D., Department of Oncology, Tom Baker Cancer Centre, University of Calgary, 1331 29th Street NW, Calgary, Alberta T2N 4N2, Canada. Telephone: 403-521-3701; E-Mail: DrSunil.Verma@ahs.ca

Received March 9, 2016. Accepted May 10, 2016. Published online before print July 1, 2016.

Disclosures of potential conflicts of interest may be found at the end of this article. Abstract Background. Palbociclib enhances endocrine therapy and improves clinical outcomes in hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC). Because this is a new target, it is clinically important to understand palbociclib’s safety profile to effectively manage toxicity and optimize clinical benefit.

Materials and Methods.
Patients with endocrine-resistant, HR-positive/HER2-negative MBC (n = 521) were randomly assigned 2:1 to receive fulvestrant (500 mg intramuscular injection) with or without goserelin with oral palbociclib (125 mg daily; 3 weeks on/1 week off) or placebo. Safety assessments at baseline and day 1 of each cycle included blood counts on day 15 for the first 2 cycles. Hematologic toxicity was assessed by using laboratory data.

A total of 517 patients were treated (palbociclib, n = 345; placebo, n = 172); median follow-up was 8.9 months. With palbociclib, neutropenia was the most common grade 3 (55%) and 4 (10%) adverse event; median times to onset and duration of grade ≥3 episodes were 16 and 7 days, respectively. Asian ethnicity and below-median neutrophil counts at baseline were significantly associated with an increased chance of developing grade 3–4 neutropenia with palbociclib. Dose modifications for grade 3–4 neutropenia had no adverse effect on progression-free survival. In the palbociclib arm, febrile neutropenia occurred in 3 (<1%) patients. The percentage of grade 1–2 infections was higher than in the placebo arm. Grade 1 stomatitis occurred in 8% of patients.

Palbociclib plus fulvestrant treatment was well-tolerated, and the primary toxicity of asymptomatic neutropenia was effectively managed by dose modification without apparent loss of efficacy. This study appears at ClinicalTrials.gov, NCT01942135. Implications for Practice: Treatment with palbociclib in combination with fulvestrant was generally safe and well-tolerated in patients with hormone receptor (HR)-positive metastatic breast cancer. Consistent with the drug's proposed mechanism of action, palbociclib-related neutropenia differs in its clinical time course, patterns, and consequences from those seen with chemotherapy. Neutropenia can be effectively managed by a dose reduction, interruption, or cycle delay without compromising efficacy. A significant efficacy gain and a favorable safety profile support the consideration of incorporating palbociclib into the routine management of HR-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.

This is the first report, to our knowledge, showing that palbociclib plus fulvestrant improves PFS in asian patients. Palbociclib plus fulvestrant was well tolerated in this study.

J Glob Oncol. 2017 Aug; 3(4): 289–303.
Published online 2017 Apr 11. doi:  10.1200/JGO.2016.008318
PMCID: PMC5560465

PALOMA-3: Phase III Trial of Fulvestrant With or Without Palbociclib in Premenopausal and Postmenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That Progressed on Prior Endocrine Therapy—Safety and Efficacy in Asian Patients

Hiroji Iwata,corresponding author Seock-Ah Im, Norikazu Masuda, Young-Hyuck Im, Kenichi Inoue, Yoshiaki Rai, Rikiya Nakamura, Jee Hyun Kim, Justin T. Hoffman, Ke Zhang, Carla Giorgetti, Shrividya Iyer, Patrick T. Schnell, Cynthia Huang Bartlett, and Jungsil Ro



To assess efficacy and safety of palbociclib plus fulvestrant in Asians with endocrine therapy–resistant metastatic breast cancer.

Patients and Methods

The Palbociclib Ongoing Trials in the Management of Breast Cancer 3 (PALOMA-3) trial, a double-blind phase III study, included 521 patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative metastatic breast cancer with disease progression on endocrine therapy. Patient-reported outcomes (PROs) were assessed on study treatment and at the end of treatment.


This preplanned subgroup analysis of the PALOMA-3 study included premenopausal and postmenopausal Asians taking palbociclib plus fulvestrant (n = 71) or placebo plus fulvestrant (n = 31). Palbociclib plus fulvestrant improved progression-free survival (PFS) compared with fulvestrant alone. Median PFS was not reached with palbociclib plus fulvestrant (95% CI, 9.2 months to not reached) but was 5.8 months with placebo plus fulvestrant (95% CI, 3.5 to 9.2 months; hazard ratio, 0.485; 95% CI, 0.270 to 0.869; P = .0065). The most common all-cause grade 3 or 4 adverse events in the palbociclib arm were neutropenia (92%) and leukopenia (29%); febrile neutropenia occurred in 4.1% of patients. Within-patient mean trough concentration comparisons across subgroups indicated similar palbociclib exposure between Asians and non-Asians. Global quality of life was maintained; no statistically significant changes from baseline were observed for patient-reported outcome scores with palbociclib plus fulvestrant.


This is the first report, to our knowledge, showing that palbociclib plus fulvestrant improves PFS in asian patients. Palbociclib plus fulvestrant was well tolerated in this study.


1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90. [PubMed]
2. Li J, Zhang BN, Fan JH, et al. A nation-wide multicenter 10-year (1999-2008) retrospective clinical epidemiological study of female breast cancer in China. BMC Cancer. 2011;11:364. [PMC free article] [PubMed]
3. American Cancer Society Breast Cancer Facts & Figures 2015-2016. http://www.cancer.org/acs/groups/content/@research/documents/document/acspc-046381.pdf
4. Youlden DR, Cramb SM, Yip CH, et al. Incidence and mortality of female breast cancer in the Asia-Pacific region. Cancer Biol Med. 2014;11:101–115. [PMC free article] [PubMed]
5. Ghiasvand R, Adami HO, Harirchi I, et al. Higher incidence of premenopausal breast cancer in less developed countries: Myth or truth? BMC Cancer. 2014;14:343. [PMC free article] [PubMed]
6. Si W, Li Y, Han Y, et al. Epidemiological and clinicopathological trends of breast cancer in Chinese patients during 1993 to 2013: A retrospective study. Medicine (Baltimore) 2015;94:e820. [PMC free article] [PubMed]
7. Swain SM, Im YH, Im SA, et al. Safety profile of pertuzumab with trastuzumab and docetaxel in patients from Asia with human epidermal growth factor receptor 2-positive metastatic breast cancer: Results from the phase III trial CLEOPATRA. Oncologist. 2014;19:693–701. [PMC free article] [PubMed]
8. Cardoso F, Costa A, Norton L, et al. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2) Ann Oncol. 2014;25:1871–1888. [PMC free article] [PubMed]
9. Early Breast Cancer Trialists’ Collaborative Group: Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet 351:1451-1467, 1998. [PubMed]
10. Ellis M. Overcoming endocrine therapy resistance by signal transduction inhibition. Oncologist. 2004;9(suppl 3):20–26. [PubMed]
11. Marzec M, Kasprzycka M, Lai R, et al. Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity. Blood. 2006;108:1744–1750. [PMC free article] [PubMed]
12. Saab R, Bills JL, Miceli AP, et al. Pharmacologic inhibition of cyclin-dependent kinase 4/6 activity arrests proliferation in myoblasts and rhabdomyosarcoma-derived cells. Mol Cancer Ther. 2006;5:1299–1308. [PubMed]
13. Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): Final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17:425–439. [PubMed]
14. Turner NC, Ro J, André F, et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med. 2015;373:209–219. [PubMed]
15. European Organisation for Research and Treatment of Cancer Quality of Life Group: EORTC QLQ-C30 (version 3). http://www.eortc.be/qol/files/C30/QLQ-C30%20English.pdf. [PubMed]
16. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365–376. [PubMed]
17. Murphy CG, Dickler MN. The role of CDK4/6 inhibition in breast cancer. Oncologist. 2015;20:483–490. [PMC free article] [PubMed]
18. Finn RS, Crown JP, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): A randomised phase 2 study. Lancet Oncol. 2015;16:25–35. [PubMed]
19. Finn RS, Martin M, Rugo HS, et al: PALOMA-2: Primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER+/HER2- advanced breast cancer (ABC). J Clin Oncol 34, 2016 (suppl; abstr 507)
21. Pfizer: IBRANCE (palbociclib). http://labeling.pfizer.com/ShowLabeling.aspx?id=2191.
22. Ling WH, Lee SC. Inter-ethnic differences: How important is it in cancer treatment? Ann Acad Med Singapore. 2011;40:356–361. [PubMed]
23. Voon PJ, Yap HL, Ma CY, et al. Correlation of aldo-ketoreductase (AKR) 1C3 genetic variant with doxorubicin pharmacodynamics in Asian breast cancer patients. Br J Clin Pharmacol. 2013;75:1497–1505. [PMC free article] [PubMed]
24. Lim HS, Ju Lee H, Seok Lee K, et al. Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer. J Clin Oncol. 2007;25:3837–3845. [PubMed]
25. Park IH, Ro J, Lee KS, et al. Phase II parallel group study showing comparable efficacy between premenopausal metastatic breast cancer patients treated with letrozole plus goserelin and postmenopausal patients treated with letrozole alone as first-line hormone therapy. J Clin Oncol. 2010;28:2705–2711. [PubMed]
26. Jung KW, Won YJ, Kong HJ, et al. Cancer statistics in Korea: Incidence, mortality, survival, and prevalence in 2011. Cancer Res Treat. 2014;46:109–123. [PMC free article] [PubMed]
27. Schlichting JA, Soliman AS, Schairer C, et al. Breast cancer by age at diagnosis in the Gharbiah, Egypt, population-based registry compared to the United States Surveillance, Epidemiology, and End Results Program, 2004-2008. BioMed Res Int. 2015;2015:381574. [PMC free article] [PubMed]
28. Villarreal-Garza C, Aguila C, Magallanes-Hoyos MC, et al. Breast cancer in young women in Latin America: An unmet, growing burden. Oncologist. 2013;18(suppl):26–34. [PubMed]
29. Villarreal-Garza C, Mohar A, Bargallo-Rocha JE, et al: Molecular subtypes and prognosis in young Mexican women with breast cancer. Clin Breast Cancer 10.1016/j.clbc.2016.11.007 [epub ahead of print on November 23, 2016] [PubMed]

Articles from Journal of Global Oncology are provided here courtesy of American Society of Clinical Oncology

Plaats een reactie ...

Reageer op "Borstkanker: Palpociclib plus fulvestrand geeft langere overall overleving en progressievrije ziekte dan alleen fulvesrtrand bij hormoonresistente borstkanker"

Gerelateerde artikelen

Gerelateerde artikelen

Bloedtest op in bloed circulerende >> POLE mutatie: veel kankerpatienten >> DRUP studie geeft bij 37 procent >> Larotrectinib geeft bijzonder >> Pembrolizumab - Keytruda geeft >> DNA mutaties komen 3x zo vaak >> HRDetect voorspelt voor 98 >> Internationale groep van 180 >> Personalised medicine door >> Nederland betaalt veel meer >>